GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » Institutional Ownership

Axsome Therapeutics (STU:19X) Institutional Ownership : 39.22% (As of Dec. 14, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Axsome Therapeutics's institutional ownership is 39.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Axsome Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Axsome Therapeutics's Float Percentage Of Total Shares Outstanding is 83.49%.


Axsome Therapeutics Institutional Ownership Historical Data

The historical data trend for Axsome Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Institutional Ownership Chart

Axsome Therapeutics Historical Data

The historical data trend for Axsome Therapeutics can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 30.99 34.10 34.80 34.60 35.58 37.31 37.60 38.85 39.04 39.22

Axsome Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Axsome Therapeutics Business Description

Traded in Other Exchanges
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines